

Synthesis of Novel Potent Nosocomial Antibiotics

Track Code: 66199

Categories:

- Medical/Health
- Pharmaceuticals

Keywords:

- Antibiotics
- Biotechnology
- Drug Development
- Medical/Health
- Pharmaceuticals

Hospital-acquired (nosocomial) infections cause or contribute to 99,000 deaths each year in the United States alone. A patient's weakened state combined with bacteria's increasing resistance to antibiotics makes these infections difficult to treat. The current suite of antibiotics available for treating serious nosocomial infections, such as MRSA, can have unwanted side effects; hence, it is important to identify new antibiotics.

Researchers at Purdue University have developed a class of antibiotic compounds designed to specifically target common nosocomial infections. By selectively targeting the mevalonate pathway of Gram-positive bacteria, these compounds will be more effective with fewer side effects. Several of the analogues also demonstrated selective antibacterial activity against MRSA and VRE, two of the most common and most dangerous nosocomial infections.

Advantages:

- Targets common nosocomial infections
- Fewer side effects

Potential Applications:

- Medical/Healthcare
- Pharmaceutical Industry
- Drug Development

People:

- Stauffacher, Cynthia (Project leader)

Intellectual Property:

Application Date: May 8, 2015
Type: CON-Patent
Country of Filing: United States
Patent Number: 9,604,925
Issue Date: March 28, 2017

Application Date: March 15, 2013
Type: Utility Patent
Country of Filing: United States
Patent Number: 9,073,832
Issue Date: July 7, 2015

Application Date: April 24, 2012
Type: Provisional-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Application Date: April 23, 2012
Type: Provisional-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org